Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) |
| recruiting |
| Phase 1 |
| 18 |
| Xi'an No.3 HospitalOTHER_GOV |
| 1 |
| Nov 25, 2025 |
| clinicaltrials |
| NCT07249073 | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06581848 | Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | active not recruiting | — | 150 | PfizerINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07236021 | e-Motion : Promoting Emotion Regulation in Chronic Cancer | recruiting | N/A | 30 | Université Libre de BruxellesOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03717844 | Registry for Adults With Plasma Cell Disorders (PCD's) | recruiting | — | 2,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR T for mYeloma(MCARTY) | recruiting | Phase 1 | 27 | University College, LondonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07180992 | Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma(MONOMM) | recruiting | — | 25 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06055894 | A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | recruiting | N/A | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03375619 | Long-term Follow-up Study of Patients Receiving CAR-T Cells | recruiting | — | 500 | Medical College of WisconsinOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04114084 | Sleep Apnea in Patients With MGUS and MM | recruiting | — | 200 | Michael TomassonOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03315026 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)(VRd MM Fibrate) | recruiting | Phase 4 | 44 | Tanta UniversityOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL(CHARKALL) | active not recruiting | Phase 1 | 54 | Baylor College of MedicineOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT00626496 | Family Study of Lymphoproliferative Disorders | recruiting | — | 3,000 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03016806 | Umbilical Cord Blood Transplantation From Unrelated Donors | recruiting | — | 30 | University of RochesterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05932680 | Limited-duration Teclistamab | recruiting | Phase 2 | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma(CaMMouflage) | recruiting | Phase 1 | 50 | Caribou Biosciences, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06409767 | Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.(ALHERT) | recruiting | N/A | 2,224 | University Hospital, AngersOTHER_GOV | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06487247 | HEME Home Transfusion Program | recruiting | N/A | 700 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | recruiting | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06133426 | Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients(BTP) | recruiting | N/A | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07045168 | Risk-adapted Therapeutic Strategy in +1q NDMM | not yet recruiting | — | 200 | FengYan JinOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06933277 | Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients | recruiting | — | 159 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | active not recruiting | — | 200 | All4CureINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06350994 | Early Assessment of Cardiac Function After Treatment With CAR-T Cells(Cardio CAR-T) | recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07014865 | Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers(MMYLIFE) | recruiting | — | 190 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Aug 29, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 26, 2025source: clinicaltrials